

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 00719)

TRADING HALT

At the request of Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”), trading in its shares on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) has been halted with effect from 11: 09 a.m. on 27 April 2022 pending the release of an announcement in relation to an inside information of the Company.

As the trading price of A shares if the Company has reached its maximum limit of increase during any trading day, its share price is restricted from further increases in accordance to the Shenzhen Stock Exchange Trading Rules notwithstanding that the A shares are permitted to continue to trade.

By Order of the Board

Shandong Xinhua Pharmaceutical Company Limited

Zhang Daiming
Chairman

27 April 2022, Zibo, the PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Zhang Daiming (Chairman)

Mr. Du Deping

Mr. He Tongqing

Independent Non-executive Directors:

Mr. Pan Guangcheng

Mr. Zhu Jianwei

Mr. Lo Wah Wai

Non-executive Directors:

Mr. Cong Kechun

Mr. Xu Lie